Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study.
Reem D MahmoodDanielle ShawTine DescampsCong ZhouRobert D MorganSaifee MullamithaMark SaundersNerissa MescalladoAlison BackenKaren MorrisRoss A LittleSusan CheungYvonne WatsonJames P B O'ConnorAlan JacksonGeoff J M ParkerCaroline DiveGordon C JaysonPublished in: BMC cancer (2021)
In patients diagnosed with colorectal cancer with liver metastases, treatment with standard chemotherapy changes cell- and protein-based biomarkers, although these changes are not associated with survival outcomes. In contrast, the imaging biomarker, Ktrans, offers promise to direct molecularly targeted therapies such as anti-angiogenic agents.
Keyphrases
- metastatic colorectal cancer
- liver metastases
- high resolution
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- magnetic resonance
- locally advanced
- prognostic factors
- stem cells
- cell therapy
- peritoneal dialysis
- squamous cell carcinoma
- randomized controlled trial
- big data
- phase ii study
- machine learning
- patient reported outcomes
- study protocol
- small molecule
- photodynamic therapy